The strong beat on both revenue and EPS, combined with maintained guidance and a growing pipeline, supports a bullish outlook. Traders should watch for continued LUPKYNIS adoption and any updates from the PRESERVE study or aritinercept trials as catalysts.
Price Chart
Executive Summary
Aurinia Pharmaceuticals reported Q2 2026 revenue of $83.2M (+19% YoY) and diluted EPS of $0.28 (+75% YoY), both exceeding consensus estimates. The company reiterated its full-year 2026 guidance for total revenue of $315M-$325M and LUPKYNIS net product sales of $305M-$315M, while also providing an update on the initiation of the PRESERVE Phase 4 study and the expansion of its aritinercept pipeline into four indications. The beat on both top and bottom lines, combined with maintained guidance, supports a positive read-through for the stock.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue of $83.2M, up 19% YoY from $70.0M
- Q2 2026 diluted EPS of $0.28, up 75% YoY from $0.16
- LUPKYNIS net product sales of $79.4M, up 19% YoY
- Net income of $37.4M, up 74% YoY from $21.5M
- Operating cash flow of $52.5M, up 19% YoY
- Cash and investments of $443.1M at June 30, 2026
- Reiterated FY 2026 guidance: total revenue $315M-$325M, net product sales $305M-$315M
- Initiated PRESERVE Phase 4 study of LUPKYNIS in combination with biologics
- Aritinercept clinical development initiated in four indications
Financial Impact
Revenue beat of ~$2.7M (3.4%) vs consensus of $80.5M; EPS beat of $0.01 (4.2%) vs consensus of $0.24
Risk Factors
- LUPKYNIS sales growth could decelerate if competition from new lupus nephritis therapies intensifies
- Clinical development of aritinercept carries inherent risk of failure or delays
- Share repurchase activity may reduce liquidity and signal management's view of undervaluation but also consumes cash
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001600620-26-000059 |
| Document: auph-20260806.htm | 0001600620-26-000059 |
| Document: 0001600620-26-000059-index-headers.html | 0001600620-26-000059 |
| Document: 0001600620-26-000059-index.html | 0001600620-26-000059 |
| Document: 0001600620-26-000059.txt | 0001600620-26-000059 |
| 8-K Data (Synthetic) | 0001600620-26-000059 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $16.13 $16.12 | ▼ −0.06% | ▼ −0.66% | $15.77 (−2.23%) |
Jun 3, 2026 17w ago | Insider Buy | $15.67 $15.80 | ▲ +0.83% | ▲ +1.95% | $15.77 (+0.64%) |
May 11, 2026 20w ago | 8-K | $15.72 $15.78 | ▲ +0.38% | ▲ +0.69% | $15.77 (+0.32%) |
Feb 26, 2026 31w ago | 8-K | $13.97 $14.60 | ▲ +4.51% | ▲ +10.91% | $15.77 (+12.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access